Shanghai Shyndec Pharmaceutical Continues to Strengthen Cooperation with SINOPHARM in Distribution and Retail Channels

Deep News

Nov 05

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) stated on November 5 in response to investor inquiries that, adhering to market-oriented principles, the company continues to enhance collaboration with SINOPHARM (01099) in distribution and retail channels. Through online coordination and participation in SINOPHARM's interconnectivity initiatives, the company is strengthening synergies with the commercial sector within the SINOPHARM Group, actively promoting "industrial-commercial collaboration."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173880572"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173880572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173880572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173880572","market":"fut","top_or_hot":-1,"title":"Shanghai Shyndec Pharmaceutical Continues to Strengthen Cooperation with SINOPHARM in Distribution and Retail Channels","media":"Deep News","content":"<p>Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) stated on November 5 in response to investor inquiries that, adhering to market-oriented principles, the company continues to enhance collaboration with SINOPHARM (01099) in distribution and retail channels. Through online coordination and participation in SINOPHARM's interconnectivity initiatives, the company is strengthening synergies with the commercial sector within the SINOPHARM Group, actively promoting \"industrial-commercial collaboration.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Shyndec Pharmaceutical Continues to Strengthen Cooperation with SINOPHARM in Distribution and Retail Channels</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Shyndec Pharmaceutical Continues to Strengthen Cooperation with SINOPHARM in Distribution and Retail Channels\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-05 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) stated on November 5 in response to investor inquiries that, adhering to market-oriented principles, the company continues to enhance collaboration with SINOPHARM (01099) in distribution and retail channels. Through online coordination and participation in SINOPHARM's interconnectivity initiatives, the company is strengthening synergies with the commercial sector within the SINOPHARM Group, actively promoting \"industrial-commercial collaboration.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1173880572","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173880572","pubTimestamp":1762347643,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) stated on November 5 in response to investor inquiries that, adhering to market-oriented principles, the company continues to enhance collaboration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600420":"国药现代","BK0239":"医药制造","BK1197":"保健护理产品经销商","BK0020":"浦东新区","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK0132":"高送转概念","BK1500":"做空集合股","BK1515":"抗疫概念","01099":"国药控股","BK0010":"央企","BK0082":"国资改革","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC"},"translate_title":"上海现代达药业继续加强与国药集团在分销和零售渠道方面的合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600420":1,"01099":1},"content_text":"Shanghai Shyndec Pharmaceutical Co., Ltd. (600420) stated on November 5 in response to investor inquiries that, adhering to market-oriented principles, the company continues to enhance collaboration with SINOPHARM (01099) in distribution and retail channels. Through online coordination and participation in SINOPHARM's interconnectivity initiatives, the company is strengthening synergies with the commercial sector within the SINOPHARM Group, actively promoting \"industrial-commercial collaboration.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}